Topical treatment of psoriasis with fludarabineNOURI, K; HAYAG, M. V; TIE, C et al.Cutis (New York, NY). 1997, Vol 59, Num 5, issn 0011-4162, p. 284Article

A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cellsKALHORN, Thomas F; REN, Aaron G; SLATTERY, John T et al.Journal of chromatography. B. 2005, Vol 820, Num 2, pp 243-250, issn 1570-0232, 8 p.Article

Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicityEISSNER, G; IACOBELLI, M; BLÜML, S et al.Bone marrow transplantation (Basingstoke). 2005, Vol 35, Num 9, pp 915-920, issn 0268-3369, 6 p.Article

Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphotic leukemiaBAY, J. O; FOUASSIER, M; BEAL, D et al.Hematology and cell therapy (Print). 1997, Vol 39, Num 4, pp 209-212, issn 1269-3286Article

Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning : Preliminary resultsTERENZI, A; ARISTEI, C; AVERSA, F et al.Transplantation proceedings. 1996, Vol 28, Num 6, issn 0041-1345, p. 3101Conference Paper

Perspectives on purine analoguesCHESON, B. D.Hematology and cell therapy (Print). 1996, Vol 38, pp S109-S116, issn 1269-3286, SUP2Article

Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosisCESARO, Simone; GAZZOLA, Maria Vittoria; MESSINA, Chiara et al.American journal of hematology. 2003, Vol 72, Num 2, pp 143-146, issn 0361-8609, 4 p.Article

Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogsVINOGRADOV, Serguei V; ZEMAN, Arin D; BATRAKOVA, Elena V et al.Journal of controlled release. 2005, Vol 107, Num 1, pp 143-157, issn 0168-3659, 15 p.Article

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaTSIMBERIDOU, Apostolia; CORTES, Jorge; THOMAS, Deborah et al.Leukemia research. 2003, Vol 27, Num 10, pp 893-897, issn 0145-2126, 5 p.Article

Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cellsFERNANDEZ-CALOTTI, Paula X; LOPEZ-GUERRA, Mónica; COLOMER, Dolors et al.Haematologica (Roma). 2012, Vol 97, Num 6, pp 943-951, issn 0390-6078, 9 p.Article

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyCARNEY, D. A; WESTERMAN, D. A; SEYMOUR, J. F et al.Leukemia. 2010, Vol 24, Num 12, pp 2056-2062, issn 0887-6924, 7 p.Article

F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfanBONIN, M; PURSCHE, S; BERGEMAN, T et al.Bone marrow transplantation (Basingstoke). 2007, Vol 39, Num 4, pp 201-206, issn 0268-3369, 6 p.Article

Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cellsMOLINA-ARCAS, M; MARCE, S; VILLAMOR, N et al.Leukemia. 2005, Vol 19, Num 1, pp 64-68, issn 0887-6924, 5 p.Article

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemiaTSIMBERIDOU, Apostolia M; KEATING, Michael J; GILES, Francis J et al.Cancer. 2004, Vol 100, Num 12, pp 2583-2591, issn 0008-543X, 9 p.Article

Expression of CD10 by b-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitroMORABITO, Fortunato; MANGIOLA, Massimo; CUTRONA, Giovanna et al.Haematologica (Roma). 2003, Vol 88, Num 8, pp 864-873, issn 0390-6078, 10 p.Article

Blanc ou rouge, il fallait choisir.. = Bullous skin rash in a 61-year-old manPHELIPPEAU, M; BONNET, D; LAURENTY, A.-P et al.La Revue de médecine interne (Paris). 2011, Vol 32, Num 2, pp 120-123, issn 0248-8663, 4 p.Article

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantationLONG-BOYLE, J. R; GREEN, K. G; BRUNSTEIN, C. G et al.Bone marrow transplantation (Basingstoke). 2011, Vol 46, Num 1, pp 20-26, issn 0268-3369, 7 p.Article

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimenBOLANOS-MEADE, J; LUZNIK, L; BRODSKY, R. A et al.Bone marrow transplantation (Basingstoke). 2009, Vol 43, Num 6, pp 477-480, issn 0268-3369, 4 p.Article

The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disordersPOLIZZOTTO, Mark N; TAM, Constantine S; MILNER, Alvin et al.Cancer. 2006, Vol 107, Num 4, pp 773-780, issn 0008-543X, 8 p.Article

Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemiaLAM, Clarence C. K; MA, Edmond S. K; KWONG, Yok-Lam et al.American journal of hematology. 2005, Vol 79, Num 4, pp 288-290, issn 0361-8609, 3 p.Article

Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53ALMAZI, Juhura G; MACTIER, Swetlana; GILES BEST, O et al.Proteomics. Clinical applications (Print). 2012, Vol 6, Num 5-6, pp 279-290, issn 1862-8346, 12 p.Article

Activity of oral fludarabine phosphate in previously treated Chronic lymphocytic leukemiaBOOGAERTS, M. A; VAN HOOF, A; VERHOEF, G et al.Journal of clinical oncology. 2001, Vol 19, Num 22, pp 4252-4258, issn 0732-183XArticle

Fludarabine may overcome resistance to rituximab in IgM-related neuropathyKOYA, Junji; IWATA, Atsushi; NAKAMURA, Fumihiko et al.Journal of the neurological sciences. 2012, Vol 315, Num 1-2, pp 150-152, issn 0022-510X, 3 p.Article

Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitroSCHMIDT-HIEBER, M; BUSSE, A; REUFI, B et al.Journal of cancer research and clinical oncology. 2009, Vol 135, Num 2, pp 227-234, issn 0171-5216, 8 p.Article

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell culturesELWI, Adam N; DAMARAJU, Vijaya L; KUZMA, Michelle L et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 2, pp 289-301, issn 0344-5704, 13 p.Article